Author

T. Hishiki

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:virus· 1

Frequent Co-Authors

D. Akazawa· 3 shared H. Ebihara· 3 shared H. Ohashi· 3 shared K. Maeda· 3 shared K. Shionoya· 3 shared K. Tsuchimoto· 3 shared K. Watashi· 3 shared T. Suzuki· 3 shared

Activity by Year

2022-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

D. Akazawa

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Identification of inosine monophosphate dehydrogenase as a potential target for anti-monkeypox virus agents

T. Hishiki, T. Morita, D. Akazawa, H. Ohashi, E.-S. Park, M. Kataoka, J. Mifune, K. Shionoya, K. Tsuchimoto, S. Ojima, A. H. Azam, S. Nakajima, T. Yoshikawa, M. Shimojima, K. Kiga, , K. Watashi

This study identifies IMPDH as a potential target for anti-monkeypox virus agents by showing that compounds targeting this enzyme inhibit MPXV replication more effectively than existing treatments.

bioRxiv · Dec 26, 2022 · PreprintMicrobiology

Potential anti-monkeypox virus activity of atovaquone, mefloquine, and molnupiravir, and their potential use as treatments

D. Akazawa, H. Ohashi, T. Hishiki, T. Morita, S. Iwanami, K. S. Kim, Y. D. Jeong, E.-S. Park, M. Kataoka, K. Shionoya, J. Mifune, K. Tsuchimoto, S. Ojima, A. H. Azam, S. Nakajima, , K. Watashi

This study identifies atovaquone, mefloquine, and molnupiravir as potential anti-monkeypox virus drugs, with atovaquone showing enhanced efficacy when combined with tecovirimat.

bioRxiv · Aug 2, 2022 · PreprintMicrobiology

Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2

H. Ohashi, T. Hishiki, D. Akazawa, K. S. Kim, J. Woo, K. Shionoya, K. Tsuchimoto, S. Iwanami, S. Moriyama, H. Kinoshita, S. Yamada, Y. Kuroda, T. Yamamoto, N. Kishida, S. Watanabe, , K. Watashi

The paper compares the efficacy of neutralizing antibodies and antiviral drugs against SARS-CoV-2 Omicron subvariants BA.1 and BA.2, finding differential responses to specific treatments.

bioRxiv · Feb 27, 2022Microbiology